Skip to main content Accessibility help
×
Home

MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER

  • Mathilda L. Bongers (a1), Dirk de Ruysscher (a2), Cary Oberije (a3), Philippe Lambin (a3), Carin A. Uyl-de Groot (a4), José Belderbos (a5) and Veerle M.H. Coupé (a6)...

Abstract

Introduction: Optimizing radiotherapy with or without chemotherapy through advanced imaging and accelerated radiation schemes shows promising results in locally advanced non–small-cell lung cancer (NSCLC). This study compared the cost-effectiveness of positron emission tomography-computed tomography based isotoxic accelerated sequential chemo-radiation (SRT2) and concurrent chemo-radiation with daily low-dose cisplatin (CRT2) with standard sequential (SRT1) and concurrent chemo-radiation (CRT1).

Methods: We used an externally validated mathematical model to simulate the four treatment strategies. The model was built using data from 200 NSCLC patients treated with curative sequential chemo-radiation. For concurrent strategies, data from a meta-analysis and a single study were included in the model. Costs, utilities, and resource use estimates were obtained from literature. Primary outcomes were the incremental cost-effectiveness and cost-utility ratio (ICUR) of each strategy. Scenario analyses were carried out to investigate the impact of uncertainty.

Results: Total undiscounted costs and quality-adjusted life-years (QALYs) for SRT1, CRT1, SRT2, and CRT2 were EUR 17,288, EUR 18,756, EUR 19,072, EUR 17,360 and QALYs 1.10, 1.15, 1.40, and 1.40, respectively. Compared with SRT1, the ICURs were EUR 38,024/QALY for CRT1, EUR 6,249/QALY for SRT2, and EUR 346/QALY for CRT2. CRT2 was highly cost-effective compared with SRT1. Moreover, CRT2 was more effective and less costly than CRT1 and SRT2. Therefore, these strategies were dominated by CRT2.

Conclusion: Optimized sequential and concurrent chemo-radiation strategies are more effective and cost-effective than the current conventional sequential and concurrent strategies. Concurrent chemo-radiation with a daily low dose cisplatin regimen is the most cost-effective treatment option for locally advanced inoperable NSCLC patients.

Copyright

References

Hide All
1. Parkin, DM, Bray, F, Ferlay, J, Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74108.
2. Vansteenkiste, J, De Ruysscher, D, Eberhardt, WEE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 (Suppl 6):vi89vi98.
3. O'Rourke, N, Roqué I Figuls, M, Farré Bernadó, N, Macbeth, F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010:CD002140.
4. De Ruysscher, D, Faivre-Finn, C, Nestle, U, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28:53015310.
5. Mauguen, A, Le Pechoux, C, Saunders, MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis. J Clin Oncol. 2012;30:27882797.
6. Koning, CC, Wouterse, SJ, Daams, JG, et al. Toxicity of concurrent radiochemotherapy for locally advanced non–small-cell lung cancer: A systematic review of the literature. Clin Lung Cancer. 2013;14: 481487.
7. Drummond, MF. Methods for the economic evaluation of health care programmes. Cambridge: Oxford University Press; 2005:404.
8. Bongers, ML, De Ruysscher, D, Oberije, C, et al. Multi-state statistical modeling: A tool to build a lung cancer micro-simulation model that includes parameter uncertainty and patient heterogeneity. Med Decis Making. 2016;36:86100.
9. Bongers, ML, Coupé, VHM, De Ruysscher, D, et al. Individualized PET-based isotoxic accelerated radiotherapy is cost effective compared to conventional radiotherapy: A model-based evaluation. Int J Radiat Oncol Biol Phys. 2015;91:857865.
10. Dehing-Oberije, C, De Ruysscher, D, Petit, S, et al. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol. 2010;97:455461.
11. Dehing-Oberije, C, De Ruysscher, D, van Baardwijk, A, et al. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol. 2009;91:421426.
12. De Ruysscher, D, Dehing, C, Yu, S, et al. Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol. 2009;91:353359.
13. Dehing-Oberije, C, Yu, S, De Ruysscher, D, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;74:355362.
14. Vanni, T, Karnon, J, Madan, J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics. 2011;29: 3549.
15. Aupérin, A, Le Péchoux, C, Rolland, E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:21812190.
16. Uyterlinde, W, Belderbos, J, Baas, C, et al. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. Clin Lung Cancer. 2013;14:541548.
17. Grutters, JPC, Pijls-Johannesma, M, Ruysscher, DD, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research. Cancer Treat Rev. 2010;36:468476.
18. Tan, SS, Bouwmans, CA, Rutten, FF, Hakkaart-van Roijen, L. Update of the Dutch Manual for Costing in Economic Evaluations. Int J Technol Assess Health Care. 2012;28:152158.
19. Polder, JJ, Barendregt, JJ, van Oers, H. Health care costs in the last year of life–The Dutch experience. Soc Sci Med. 2006;63:17201731.
20. Timmer-Bonte, JNH, Adang, EMM, Termeer, E, Severens, JL, Tjan-Heijnen, VCG. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol. 2008;26:290296.
21. Timmer-Bonte, JNH, Adang, EMM, Smit, HJM, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24:29912997.
22. Sturza, J. A review and meta-analysis of utility values for lung cancer. Med Decis Making. 2010;30:685693.
23. Nafees, B, Stafford, M, Gavriel, S, Bhalla, S, Watkins, J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.
24. Marseille, E, Larson, B, Kazi, DS, Kahn, JG, Rosen, S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118124. doi: http://dx.doi.org/10.2471/BLT.14.138206
25. De Ruysscher, D, van Baardwijk, A, Steevens, J, et al. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study. Radiother Oncol. 2012;102:228233.
26. Belderbos, J, Uitterhoeve, L, van Zandwijk, N, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972–22973). Eur J Cancer. 2007;43:114121.
27. Lievens, Y, Kesteloot, K, Van den Bogaert, W. CHART in lung cancer: Economic evaluation and incentives for implementation. Radiother Oncol. 2005;75:171178.
28. Ramaekers, BLT, Joore, MA, Lueza, B, et al. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients. J Thorac Oncol. 2013;8:12951307.
29. Whyte, S, Walsh, C, Chilcott, J. Bayesian calibration of a natural history model with application to a population model for colorectal cancer. Med Decis Making. 2011;31:625.
30. Driessen, EJ, Bootsma, GP, Hendriks, LE, et al. Stage III non-small cell lung cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. Radiother Oncol. 2016;121:2631.

Keywords

Type Description Title
WORD
Supplementary materials

Bongers et al supplementary material
Figures S1-S5 and Tables S1-S6

 Word (1.8 MB)
1.8 MB

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed